Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time?
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Approximately 30–40% of people with type 2 diabetes mellitus develop chronic kidney disease. This is characterised by elevated blood pressure, declining kidney function and enhanced cardiovascular morbidity and mortality. Increased albuminuria and decreasing estimated glomerular function has to be evaluated regularly to diagsnose kidney disease. New biomarkers may facilitate early diagnosis and provide infomation on undlying pathology thereby supporting early precision intervention for the optimal benefit. A number of biomarkers have been suggested but are not yet implemented in clinical practice. iI the future such bimarkers may pave the way for personalized treatment.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 151430 |
Tidsskrift | Seminars in Nephrology |
Vol/bind | 43 |
Udgave nummer | 3 |
ISSN | 0270-9295 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Copyright © 2023 Elsevier Inc. All rights reserved.
ID: 381063649